title: Targeting myeloid cells using nanoparticles to improve cancer immunotherapy.
abstract: While nanoparticles have traditionally been used to deliver cytotoxic drugs directly to tumors to induce cancer cell death, emerging data suggest that nanoparticles are likely to generate a larger impact on oncology through the delivery of agents that can stimulate antitumor immunity. Tumor-targeted nanocarriers have generally been used to localize chemotherapeutics to tumors and thus decrease off-target toxicity while enhancing efficacy. Challengingly, tumor heterogeneity and evolution render tumor-intrinsic approaches likely to succumb to relapse. The immune system offers exquisite specificity, cytocidal potency, and long-term activity that leverage an adaptive memory response. For this reason, the ability to manipulate immune cell specificity and function would be desirable, and nanoparticles represent an exciting means by which to perform such manipulation. Dendritic cells and tumor-associated macrophages are cells of the myeloid lineage that function as natural phagocytes, so they naturally take up nanoparticles. Dendritic cells direct the specificity and potency of cellular immune responses that can be targeted for cancer vaccines. Herein, we discuss the specific criteria needed for efficient vaccine design, including but not limited to the route of administration, size, morphology, surface charge, targeting ligands, and nanoparticle composition. In contrast, tumor-associated macrophages are critical mediators of immunosuppression whose trans-migratory abilities can be exploited to localize therapeutics to the tumor core and which can be directly targeted for elimination or for repolarization to a tumor suppressive phenotype. It is likely that a combination of targeting dendritic cells to stimulate antitumor immunity and tumor-associated macrophages to reduce immune suppression will impart significant benefits and result in durable antitumor responses.
authors.affiliation: Department of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Microbiology & Immunobiology, Harvard Medical School, Boston, MA 02215, USA.
authors.forename: Zohreh
authors.initials: Z
authors.lastname: Amoozgar
authors.affiliation: Department of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Microbiology & Immunobiology, Harvard Medical School, Boston, MA 02215, USA. Electronic address: michael_goldberg1@dfci.harvard.edu.
authors.forename: Michael S
authors.initials: MS
authors.lastname: Goldberg
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology; D016503:Drug Delivery Systems; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D022423:Myeloid Cells / Q000276:immunology*; D053758:Nanoparticles; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D019496:Cancer Vaccines
keywords: Cancer immunotherapy; Dendritic cells; Myeloid cells; Targeted nanoparticle delivery; Tumor-associated macrophages